SPH
SPH
A national pharmaceutical industry group headquartered in Shanghai
Shanghai Pharmaceutical Group Corporation Limited (the Company) (HKSE stock code: 02607; SSE stock code: 601607) is a national pharmaceutical industry group headquartered in Shanghai. The Company's main business covers pharmaceutical research and development and manufacturing, distribution and retailing, with an operating income of 105.5 billion yuan in 2015, the Company's overall ranking is among the best in China, and it is one of the few listed pharmaceutical companies in China with a leading position in both the pharmaceutical products and distribution markets, selected as a sample stock of the SSE 180 Index and the CSI 300 Index, and its H shares are selected as a constituent stock of the Hang Seng Index, a constituent stock of the Morgan Stanley China Index ( (MSCI).
- All
- News
- Analysis
- Research
Briefing Yesterday 10:21 AM
· Healthcare
Microchip diabetes mellitus new drug glipizide sodium approved in China
Briefing Oct 08, 2021 10:27 AM
· Healthcare
Yiyi biological submitted ryzneuta to the European drug administration ™ Listing application accepted
In depth
Healthcare
Bid for Molecular Tech in China's Early-Stage Cancer Detection Market
China, with a population of 1.4 billion, has one of the largest gene pools in the world. How does its DNA tech-based cancer detection industry look? Listed on Nasdaq in 2020, Genetron Holdings Limited (Genetron Health) is taking a leading role.
Sep 09, 2020 03:08 PM
Briefing Oct 05, 2021 09:50 AM
· Healthcare
After the layout of gene therapy track, Takeda reached a cooperation with selecta for more than US $1.1 billion
Briefing Sep 30, 2021 02:41 PM
· Healthcare
AstraZeneca acquires Caelum Biosciences overweight rare diseases business
Apr 22, 2021 03:11 PM
Research
Consumer Staples, Technology, HealthcareWIA2020 | Rising Tech Stars 2020: Global & China's 100
Dec 09, 2020 09:57 AM
Dec 09, 2020 09:39 AM
Research
Consumer Discretionary, Consumer Staples, IndustrialsTech for Global, Globalization Footprints of the Established and the New
May 29, 2020 08:30 PM
Briefing Sep 27, 2021 11:57 AM
· Healthcare
Triarm therapeutics completed a round of financing of US $60 million
Briefing Sep 18, 2021 09:08 AM
· Healthcare
Puri benchmark obtained 150 million yuan of round B financing to promote the research and development of new drugs driven by multi omics data mining
Briefing Sep 13, 2021 02:15 PM
· Healthcare
Baiji Shenzhou welcomes the milestone of "going to sea" again, and PD-1 monoclonal antibody baizean ® The new drug marketing application for esophageal squamous cell carcinoma was accepted by FDA
Briefing Sep 03, 2021 05:42 PM
· Healthcare
Nuocheng Jianhua and kangnoah deepen strategic cooperation and develop first in class macromolecular innovative drugs
Insight
Briefing Sep 03, 2021 09:45 AM
· Healthcare
Yao Ming Ju Nuo Rui Qi orenzai was approved as the second car-t product in China
Briefing Sep 03, 2021 09:38 AM
· Healthcare
Baiji Shenzhou zebutinib new indications approved by FDA
Briefing Sep 03, 2021 09:18 AM
· Healthcare
China's first generic drug of sitagliptin using biosynthesis technology was approved
Insight
Healthcare
Genetron Health's Self-Developed Mutation Capsule Differentiates It from Others
Since the outbreak of COVID-19, new public health systems and advanced biotechnology have been swiftly hyped up. Genetron Health has been able to generate a surging revenue in these special social circumstances.
May 26, 2021 05:17 AM
Healthcare
Sinopharm COVID Vaccine Receives WHO Emergency Use Certification
The Sinopharm Group’s COVID Vaccine is the sixth vaccine to receive safety, efficacy and quality verification from the World Health Organization (WHO). It is the first vaccine from a non-Western country to receive WHO certification.
May 11, 2021 03:35 AM
Briefing Jul 19, 2021 04:38 PM
Fitch confirmed that Wanzhou International, the parent company of Shuanghui, is rated as' BBB + 'with a stable outlook.
Briefing Updated 2 hours ago
· Healthcare
Kangyuan obtained tens of millions of yuan of round a financing for a long time and accelerated the application of jy108 dual anti drug ind
See more
Related Companies
EqualOcean Analysis
- Black Swans and Breakthroughs: China's Top 50 Innovative Public Firms in 2020
- China Speed: Two COVID-19 Vaccines Recognized by WHO
- After China's BNR and GTH Hit Nasdaq, Pan-Cancer Detector GRAIL Eyes IPO
- More Room for the Medical Device Market to Grow in China
- Tong Ren Tang: Any Hope for this Purveyor of Centuries-Old Chinese Medicines?
EqualOcean is an information service provider and investment research company that aims to become a global platform for industrial innovation. Founded in February 2014 and headquartered in Beijing, with a client network covering over 50 countries, the firm provides comprehensive professional services, including industry research, investment analysis, innovation consulting, data products, corporate branding and international strategy.